There had recently been much evolution in the treatment of esophageal cancer. Among changes has been greater recognition of Xeloda and of Oxapliplatin as effective drugs.
The REAL trial enrolled 1,002 patients with locally advanced (inoperable) or metastatic cancer of the esophagus, esophagogastric junction, or stomach.
Patients were assigned to one of four treatment groups:
ECF (Ellence® (epirubicin), cisplatin, and 5-FU)
ECX (Ellence, cisplatin, and Xeloda)
EOF (Ellence, Eloxatin, and 5-FU)
EOX (Ellence, Eloxatin, and Xeloda)
One-year survival was 37.7% for ECF, 40.8% for ECX, 40.4% for EOF, and 46.8% for EOX.
Progression-free survival and response rates did not differ significantly across treatment groups. Overall survival was longer with EOX than with ECF.
In response to favorable Phase III trials (ML 17032 and REAL 2), the NCCN recently added oral fluoropyrimidine, Capecitabine (Xeloda®, Roche) as an option for treatment of esophageal and gastric cancer. The REAL 2 study, the largest ever phase III study in advanced esophageal and gastric cancer, found that Capecitabine may replace 5-FU and Oxaliplatin may replace Cisplatin in triplet regimens used for the treatment of advanced esophageal and gastric cancer.
In regard to adding Avastin, there is an ongoing trial: NCT00447330. Thus I can say that Xeloda is not experimental alone or with oxaliplatin but it is experimental if used with Avastin.
Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine. 2008;358:36-46.
R. Quek, W. T. Lim, K. F. Foo, W. H. Koo, H. C. Toh Capcitabine and oxaliplatin (XELOX) in the treatment of advanced gastric cancer.Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006: 14089
nccn.org, esophageal
Please kindly delete the comment with a link to my site posted on March 29, 2011 at 11:00 PM. Will appreciate your quick response.
Posted by: Lisa Stalin | December 20, 2011 at 03:54 AM